Gemcitabine Injection Ip 200 Mg

Gemcitabine Injection Ip 200 Mg
Gemcitabine Injection Ip 200 Mg
Product Code : 0111
Rs 450/ Vial INR
Price And Quantity
Price :
Rs 450/ Vial INR
Product Specifications
Drug Type :
Drug Solutions
Ingredients :
Gemcitabine 200 mg
Physical Form :
Liquid
Function :
Anti-Cancer
Dosage :
injection
Dosage Guidelines :
As guided by physician
Quantity :
gemcitabine 200 mg Boxes
Storage Instructions :
Room Temperature (25 C Temperature)
Product Description
Qualitative and quantitative composition :
  • One vial contains gemcitabine hydrochloride equivalent to 200 mg gemcitabine.
  • After reconstitution, the solution contains 38 mg/ml of gemcitabine.
  • Excipients
  • Each 200 mg vial contains 3.5 mg (<1 mmol) sodium.
  • Pharmaceutical form
  • Powder for solution for infusion.
  • White to off-white plug or powder.
Clinical particulars :
  • Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.
  • Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
  • Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.
  • Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.
  • Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Qualitative and quantitative composition :
  • One vial contains gemcitabine hydrochloride equivalent to 200 mg gemcitabine.
  • After reconstitution, the solution contains 38 mg/ml of gemcitabine.
  • Excipients
  • Each 200 mg vial contains 3.5 mg (<1 mmol) sodium.
  • Pharmaceutical form
  • Powder for solution for infusion.
  • White to off-white plug or powder.
Clinical particulars :
  • Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.
  • Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
  • Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.
  • Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.
  • Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Contact Us

507-508, 5th Floor, The Emporio by Kunj, Opposite 4D Square Mall, Near Vishwakarma Engineering College, Visat-Gandhinagar Highway, Chandkheda, Ahmedabad, Gujarat, 382424, India
Phone :+919901290067